Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

physicians prescribing VELCADE," said Christophe Bianchi, M.D., Executive Vice President, Commercial, Millennium. "The future of VELCADE is even more exciting as we look to expand into front-line multiple myeloma with several combinations that have the potential to deliver the strongest long- term survival for patients."

-- Phase III VISTA Trial in Front-Line Multiple Myeloma (MM) -- The

Company announced that the results of the large, randomized, Phase III

VISTA trial in patients with newly diagnosed MM showed that the therapy

of VELCADE, melphalan and prednisone demonstrated a highly

statistically significant improvement, compared with melphalan and

prednisone alone, across all efficacy endpoints, including time to

progression, complete remission rate, progression free survival and

overall survival. Side effects were manageable and included those seen

in previous VELCADE trials. Based on these positive data, the control

arm of the trial was stopped early to allow patients still being

treated with melphalan and prednisone to have VELCADE added to their

therapy. The Company now expects to file a supplementary new drug

application (sNDA) for use of VELCADE in patients with newly diagnosed

MM in December 2007.

-- Compendia Listing in Front-Line MM -- In October 2007, the national

compendia organization DrugPoints Systems included VELCADE as a

recommended therapy for use in newly diagnosed multiple myeloma

patients.

-- Label Expansion in MM -- In October 2007, the U.S. Food and Drug

Administration (FDA) granted approval for VELCADE use, without dose

adjustments, in patients with impaired kidney function, including those

requiring dialysis. Impaired kidney function is a common complication

related to MM, affecting approximately 30 percent of patients at

diagnos
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander Group, ... professional service industries alike-- typically known for its consummate professionalism-- embarks each year ... cause and break from their day jobs. , "Our motto has always been ...
(Date:7/3/2015)... 3, 2015 Forskere ... Innovation in Science", som finner sted i ... på nett, på  http://www.openinnovationinscience.at , og søknadsperioden ... De to største utfordringene innen helsevitenskapen ... nye forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, ...
(Date:7/2/2015)... ... ... in countless labs for decades. In the past, people had to go to a ... a daunting and tiring process looking at endless data tables and charts. Often time’s, ... catalog structure. , Now thanks to FireflySci, scientists are throwing away those old books and ...
(Date:7/2/2015)... GLASGOW, Scotland , July 2, 2015 ...   Bio-tech procurement company Amici Procurement has ... IOM) to help it move to Office 365. ... Procurement provides small to medium-sized companies in the ... with all aspects of the purchasing cycle to help ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2Biotech Procurement Company Moves to Office 365 with iomart 2
...  MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... to sell convertible notes and warrants has been ... commenced on October 15, 2011, the Company received ...
... Dec. 27, 2011  While many Americans are resolving to address ... shows that some adults are looking to find answers to ... The survey, which was commissioned by Identigene, the ... Identigene DNA Paternity Test, the only paternity test available at ...
... 27, 2011 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... families nationwide and internationally, is pleased to announce it has ... Las Vegas laboratory for the National Children,s Leukemia Foundation (NCLF), ...
Cached Biology Technology:MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 2Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 3Cord Blood America Announces Exclusive Agreement With National Children's Leukemia Foundation to Store Stem Cells 2
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... Applied scientists demonstrated a new method for developing wrinkled ... a focused ion beam. By controlling the direction and ... patterns on flat areas of polydimethylsiloxane, a silicon-based organic ... Silly Putty). The technique has potential use for biological ...
... antiviral drugs, oseltamivir and zanamivir, are highly effective ... the spread of the influenza virus, according to ... Fred Hutchinson Cancer Research Center, University of Michigan ... print edition of the American Journal of Epidemiology. ...
... power of the sun could be available for the treatment of ... be seen whether the drug will be the revolution in prostate ... (DN-101), is based on vitamin D and is given to patients ... Drug makers came up with the idea because vitamin D ...
Cached Biology News:Applied scientists create wrinkled 'skin' on polymers 2Antivirals effectively curb influenza virus 2Antivirals effectively curb influenza virus 3Sunshine pill for prostate cancer in 2009 2
...
... Ham's F12K medium with 2 mM L-glutamine and ... order to keep the antigens in their native ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... an aqueous solution that contains a purified ... a PBS buffer (phosphate buffered saline), pH ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer provides optimum performance for both microsphere ...
Biology Products: